Systemic Lupus Erythematosus (With and Without Nephritis)
Immunology·MeSH: Lupus Erythematosus, Systemic
Prevalence
72.0 / 100K
Incidence
5.1 / 100K/yr
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| ALLO-329 | Allogene Therapeutics, Inc. (ALLO) |
Frequently asked questions
How many drugs are in development for Systemic Lupus Erythematosus (With and Without Nephritis)?
BioSniper tracks 1 drug in development for Systemic Lupus Erythematosus (With and Without Nephritis) across 1 company.
How many clinical trials target Systemic Lupus Erythematosus (With and Without Nephritis)?
There are 1 clinical trial targeting Systemic Lupus Erythematosus (With and Without Nephritis) tracked by BioSniper.
What is the prevalence of Systemic Lupus Erythematosus (With and Without Nephritis)?
The estimated prevalence of Systemic Lupus Erythematosus (With and Without Nephritis) is approximately 72.0 per 100,000 population.
Deep-dive into Systemic Lupus Erythematosus (With and Without Nephritis)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis